Navigation Links
Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
Date:6/28/2011

HOBOKEN, N.J., June 28, 2011 /PRNewswire/ -- Octapharma USA recently hosted an International Physician Advisory Board in New York City, bringing together medical experts from around the world who have extensive experience internationally with taking care of patients with von Willebrand's Disease (VWD). As the most common inherited bleeding disorder in humans, VWD affects one to two percent of the general population or approximately 3 million people in the United States.

Octapharma manufactures wilate®, a therapy introduced to the U.S. market for VWD over the last year that has been available in many other countries for a decade. The U.S. Food and Drug Administration (FDA) has granted Octapharma orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for VWD.

"Our goal was to promote a scientific dialogue among the medical community in the U.S. and abroad," said Octapharma USA President Flemming Nielsen. "Overall the advisory meeting's clinical platform encouraged significant discussion and debate around the treatment and management of VWD patients and evaluated data and experiences in Europe. There was general agreement among the attendees that improving the care for VWD patients is possible and that more data either from clinical trials or scientific experience would be beneficial."

The meeting was jointly chaired by Jerry S. Powell, M.D., Professor at the University at California-Davis and Director of the UC-Davis Hemophilia and Thrombosis Center; and John Pasi, M.D., Professor of Haemostasis and Thrombosis, Barts and The London School of Medicine and Dentistry, London.

"As physicians, we need to continue to gain experience in treating all clinical concerns of all types of VWD patients in the U.S.," said Dr. Powell. "For years, treatment options in the U.S. have been extremely limited so the opportunity to learn from our European colleagues, who have extensive experience in VWD and the use of wilate®, was quite valuable. Taking advantage of the lessons learned in Europe and determining how the clinical data can lead to improved treatment options will be beneficial to U.S. patients."

Dr. Pasi discussed the significant VWD experience at the Royal London Haemophilia Centre and the organization's decision to utilize wilate® as its primary therapy.

"Wilate® is the first double-virus inactivated VWF/FVIII high-purity concentrate, utilizing the solvent/detergent process and a special terminal dry-heating system," said Dr. Pasi. "We believed wilate® was truly a next generation therapy because it was double-virus inactivated. Our desire to utilize a factor concentrate specifically designed to treat VWD also weighed heavily in the decision as did clinical trial experience."

The Advisory Board Meeting is the latest step in Octapharma's continuing support for educational programs designed to enhance treatment for VWD patients. In the last year, Octapharma has supported educational symposia at the Annual Meeting of the National Hemophilia Foundation and a Continuing Education initiative of the National Home Infusion Association focusing on VWD.

"With several of the world's most respected VWD scientific experts on hand, attendees were able to exchange ideas and experiences that were truly valuable," said Nielsen. "Scientific and clinical advancements and unmet needs in the treatment of VWD patients are paramount challenges. All participants were truly concerned with better controlling patient bleeding episodes and improving the quality of life for VWD patients, underscoring the need for continued scientific research."

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam®  (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
Breaking Medicine News(10 mins):